Home Cart Sign in  
Chemical Structure| 1445993-26-9 Chemical Structure| 1445993-26-9

Structure of Mivebresib
CAS No.: 1445993-26-9

Chemical Structure| 1445993-26-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mivebresib, also known as ABBV-075, is an inhibitor of bormodomain and extra terminal domain (BET). The Ki values of BRD2, BRD4, BRDT are 1 nM - 2.2 nM.

Synonyms: ABBV-075

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mivebresib

CAS No. :1445993-26-9
Formula : C22H19F2N3O4S
M.W : 459.47
SMILES Code : CCS(=O)(NC1=CC=C(OC2=CC=C(F)C=C2F)C(C3=CN(C)C(C4=C3C=CN4)=O)=C1)=O
Synonyms :
ABBV-075
MDL No. :MFCD30377200
InChI Key :RDONXGFGWSSFMY-UHFFFAOYSA-N
Pubchem ID :71600087

Safety of Mivebresib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Mivebresib

epigenetics

Isoform Comparison

Biological Activity

Target
  • BET

In Vitro:

Cell Line
Concentration Treated Time Description References
Ty-82 cells 1 µM 12 or 24 hours To investigate the effect of Mivebresib on IDO1 mRNA expression, results showed that Mivebresib significantly reduced IDO1 mRNA expression. Cell Death Dis. 2019 Jul 19;10(8):557.
SKOV3 cells 1 µM 24 hours To investigate the effect of Mivebresib on IDO1 protein expression, results showed that Mivebresib significantly reduced IDO1 protein expression. Cell Death Dis. 2019 Jul 19;10(8):557.
SCLC cell lines 30 nM to >10 µM (IC50) 3 days To evaluate the antiproliferative effects of Mivebresib on different SCLC cell lines, the results showed IC50 values ranging from 30 nmol/L to >10 µmol/L, indicating cell line-specific sensitivity to BET inhibition. Mol Cancer Res. 2024 Aug 2;22(8):689-698.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Balb/c Nude mice Human Ty-82 xenograft model Oral 0.5 mg/kg Once daily for 21 days To investigate the effect of Mivebresib on tumor growth and IDO1 expression, results showed that Mivebresib significantly inhibited tumor growth and reduced IDO1 expression. Cell Death Dis. 2019 Jul 19;10(8):557.
NSG mice MOLM13/GFP-Luc cell xenograft model Oral 1 mg/kg Once daily for 2 weeks To evaluate the anti-leukemia activity of ABBV-075 and/or ABT-199 against AML xenograft models, results showed that combination treatment significantly reduced AML xenograft growth and improved survival of mice. Blood Cancer J. 2019 Jan 15;9(2):4.
Mice Subcutaneous xenograft model Intraperitoneal injection 100 mg/kg Once daily for 5 days, followed by 2 days off, repeated To evaluate the effect of Mivebresib on neuroblastoma xenograft models Mol Cancer. 2023 May 29;22(1):88

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.18mL

0.44mL

0.22mL

10.88mL

2.18mL

1.09mL

21.76mL

4.35mL

2.18mL

References

 

Historical Records

Categories